HRT prescriptions from Private Healthcare Providers
The British Menopause Society educates and supports healthcare professionals to ensure that women who require HRT can access treatment safely. The necessary guidelines are available on the website for all healthcare professionals and are not restricted to members. The clinicians at Nairn Healthcare Group follow these guidelines when prescribing HRT.
Should your private menopause clinic advise “outside of license” HRT, these prescriptions must continue to be prescribed by your private provider, as the responsibility for “out of license” prescriptions must remain with that clinical team.
Nairn Healthcare Group will not provide prescriptions for “out of license” HRT prescriptions recommended by a non-NHS health care provider.
https://thebms.org.uk/2022/12/bms-statement-hrt-prescribing/
“The British Menopause Society is aware that high doses of oestrogen are being provided routinely to women in some clinics. This could increase the risk of abnormal bleeding requiring investigation, endometrial hyperplasia and endometrial cancer. Most women will respond to licensed doses, and it is important to make women aware that some symptoms, such as low mood and anxiety may have other causes and may require other additional treatments. This is safer than increasing the amount of oestrogen provided (outside of license).
The MHRA recommends using the lowest dose of oestrogen that controls menopausal symptoms. Length of use depends on an individual’s circumstances and dosage recommendations are to ensure patient safety. There are no guidelines which recommend that the dose of oestrogen provided should be increased out of license or that different forms of oestrogen should be added together to control symptoms.
In the event of a significant event occurring (such as endometrial hyperplasia or cancer) in women using different formulations of oestrogen, outside of license, the prescribing clinicians are responsible for having put patient safety at risk. Higher doses of oestrogen require a higher dose of progestogen to ensure adequate endometrial protection (BMS Tools for Clinicians: Progestogens and endometrial protection)”